M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Summary

This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

• Metastatic Colorectal Carcinoma
• Metastatic Lung Small Cell Carcinoma
• Metastatic Malignant Solid Neoplasm
• Metastatic Pancreatic Carcinoma
• Refractory Colorectal Carcinoma
• Refractory Lung Small Cell Carcinoma
• Refractory Malignant Solid Neoplasm
• Refractory Pancreatic Carcinoma
• Stage III Colorectal Cancer AJCC v8
• Stage III Lung Cancer AJCC v8
• Stage III Pancreatic Cancer AJCC v8
• Stage IV Colorectal Cancer AJCC v8
• Stage IV Lung Cancer AJCC v8
• Stage IV Pancreatic Cancer AJCC v8
• Unresectable Colorectal Carcinoma
• Unresectable Lung Small Cell Carcinoma
• Unresectable Malignant Solid Neoplasm
• Unresectable Pancreatic Carcinoma

Interventions

DRUG

Berzosertib

Given IV

PROCEDURE

Biopsy Specimen

Undergo biopsy

PROCEDURE

Biospecimen Collection

Correlative studies

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Irinotecan Hydrochloride

Given IV

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Liza C Villaruz · University of Pittsburgh Cancer Institute LAO

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-07-22

Primary Completion

2023-03-07

Completion

2027-03-06

Countries

• United States

Study Locations